Hypogonadism causes bone loss and increased bone metastases in a model of mixed osteolytic/osteoblastic metastases: Prevention by zoledronic acid

被引：0
|
作者：
Padalecki, SS [1 ]
Carreon, M [1 ]
Grubbs, B [1 ]
Guise, TA [1 ]
机构：
[1] Univ Texas, Hlth Sci Ctr, San Antonio, TX 78285 USA
来源：
JOURNAL OF BONE AND MINERAL RESEARCH | 2004年 / 19卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1589 / 1590
页数：2
相关论文
共 50 条
  • [21] Recommendations for zoledronic acid treatment of patients with bone metastases
    Berenson, JR
    ONCOLOGIST, 2005, 10 (01): : 52 - 62
  • [22] Bone metastases and zoledronic acid: systematic review of the literature
    Ladouceur, Roger
    MEDECINE PALLIATIVE, 2005, 4 (03): : 118 - 124
  • [23] Long interval zoledronic acid use in bone metastases
    Das, Manjulika
    LANCET ONCOLOGY, 2017, 18 (02): : E72 - E72
  • [24] Zoledronic acid in lung cancer with bone metastases: a review
    Isla, Dolores
    Afonso, Ruth
    Bosch-Barrera, Joaquim
    Martinez, Natividad
    EXPERT REVIEW OF ANTICANCER THERAPY, 2013, 13 (04) : 421 - 426
  • [25] New model for the induction of osteoblastic bone metastases in rat
    Liepe, K
    Geidel, H
    Haase, M
    Hakenberg, OW
    Runge, R
    Kotzerke, J
    ANTICANCER RESEARCH, 2005, 25 (2A) : 1067 - 1073
  • [26] Efficacy of zoledronic acid in the prevention of bone metastases in patients with locally advanced prostate cancer
    Musaev, T. N.
    Zeinalov, B. S.
    Kerimov, A. Kh.
    Guliev, F. A.
    Musaev, I. N.
    Alizade, A. M.
    Adzhalov, O. V.
    ONKOUROLOGIYA, 2011, 7 (01): : 62 - 65
  • [27] Osteonecrosis of the jaw in cancer patients with bone metastases treated with zoledronic acid: The focus is prevention
    Vormola, R.
    Ortega, C.
    Montemurro, F.
    Faggiuolo, R.
    Nanni, D.
    Goia, F.
    Aglietta, M.
    ANNALS OF ONCOLOGY, 2006, 17 : XI72 - XI72
  • [28] Adrenomedullin is made by prostate cancers and increases both osteolytic and osteoblastic bone metastases.
    Mohammad, KS
    Wang, Z
    Martinez, A
    Corey, E
    Vessella, RL
    Guise, TA
    Chirgwin, JM
    JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 : S25 - S25
  • [29] Population pharmacokinetic model for zoledronic acid (zometa) in patients with bone metastases.
    Booth, BP
    Rahman, A
    Ibrahim, A
    Scher, N
    Williams, G
    Schran, H
    Ma, P
    Hsu, C
    Gobburu, JV
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (02) : P67 - P67
  • [30] A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases
    Berenson, JR
    Vescio, RA
    Rosen, LS
    VonTeichert, JM
    Woo, M
    Swift, R
    Savage, A
    Givant, E
    Hupkes, M
    Harvey, H
    Lipton, A
    CLINICAL CANCER RESEARCH, 2001, 7 (03) : 478 - 485
12345